ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO672

Disruption of the EF-Hand Domain of Polycystin-2 Ameliorates Cystic Disease Caused by Polycystin-1 Deficiency

Session Information

Category: Genetic Diseases of the Kidney

  • 1001 Genetic Diseases of the Kidney: Cystic

Authors

  • Krappitz, Matteus, Yale School of Medicine, New Haven, Connecticut, United States
  • Hollmann, Till Amadeus, Yale School of Medicine, New Haven, Connecticut, United States
  • Rümmele, David R., Friedrich-Alexander-Universität Erlangen-Nürnberg, Detmold, Germany
  • Staudner, Tobias, Friedrich-Alexander-Universität Erlangen-Nürnberg, Detmold, Germany
  • Dong, Ke, Yale School of Medicine, New Haven, Connecticut, United States
  • Fedeles, Sorin V., Yale University School of Medicine, New Haven, Connecticut, United States
  • Gallagher, Rachel, Yale University School of Medicine, New Haven, Connecticut, United States
  • Cai, Yiqiang, Yale University School of Medicine, New Haven, Connecticut, United States
  • Zhang, Chao, Yale School of Medicine, New Haven, Connecticut, United States
  • Somlo, Stefan, Yale University , New Haven, Connecticut, United States
Background

Polycystin-2 (PC2/TRPP2), the product of one of the genes mutated in ADPKD, is expressed in the endoplasmic reticulum (ER) and ciliary membranes. The COOH-terminal tail of PC2 contains a potential Ca2+ binding EF-hand motif. A mouse model termed Pkd2TEAA, in which critical residues at the EF-hand were substituted with alanine (T769A, E772A) to inactivate the Ca2+-binding properties of PC2-EF, was generated via CRISPR/Cas9 methodology [ASN2017, TH-PO597]. The Pkd2TEAA mutant does not result in loss of PC2 function as evidenced by the lack of cysts in Pkd2TEAA/TEAA animals. In this study we assessed the impact of the Pkd2TEAA allele on Pkd1 derived cysts.

Methods

The Pkd1R2220W human REJ mutant (Pkd1RW) is a representative candidate of a PC1 hypomorphic missense mutation as it leads to a clear yet partial defect in PC1 biogenesis and cleavage. Mutant alleles were further modified by insertion of a V5 epitope tag in-frame at the C-terminus to detect the mutant proteins (Pkd1RW-V5 and Pkd2TEAA-V5). The Pkd2TEAA mouse was crossed onto a Pkd1RW/flox background under the control of Pkhd1-Cre (collecting duct-specific). The kidneys were examined by histological and morphological parameters.

Results

Compared to Pkd1RW/flox; Pkhd1-Cre mice, the kidneys at P24 from Pkd1RW/flox; Pkd2TEAA/+; Pkhd1-Cre mice displayed a decreased KW/BW ratio (0.16 ± 0.02 vs 0.067 ± 0.04, ***p<0.001) and BUN (mg/dL: 93.6 ± 24.97 vs. 38.6 ± 19.54, **p<0.0013). We observed a marked increase in apoptosis specifically in cyst-lining epithelia expressing Pkd2TEAA. No significant difference in the protein levels of PC1 or PC2 proteins could be detected between the different genotypes.

Conclusion

Inactivation of the Ca2+-binding properties of PC2 EF-hand on a partially PC1 deficient background results in improved cystic phenotype possibly via specific apoptosis of PC1 mutant cyst-lining epithelial cells. Modulators of PC2 EF-hand function may alter PC2 function in vivo to slow cyst progression in the setting of some PC1 missense mutations.

Funding

  • NIDDK Support